Elixirgen Therapeutics Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $8.2M

  • Investors
  • 2

Elixirgen Therapeutics General Information

Description

Developer of stem cell therapies designed for treating syndrome and Alzheimer's diseases through regenerative and rejuvenating medicines. The company's services focus on developing therapeutics from protein-based cells that utilize chromosomal features for increasing body immunity, screening DNA structures and eliminating drug-resistant bacteria and viruses, enabling medical researchers to get protein-cell-based therapies for curing chronic telomere diseases.

Contact Information

Website
www.elixirgentx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 855 North Wolfe Street
  • Suite 619
  • Baltimore, MD 21205
  • United States
+1 (443)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 855 North Wolfe Street
  • Suite 619
  • Baltimore, MD 21205
  • United States
+1 (443)

Elixirgen Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Elixirgen Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 13-Nov-2025 $8.2M Completed Clinical Trials - Phase 2
4. Later Stage VC (Series A3) 09-Nov-2023 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 17-Feb-2021 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series B) 15-Nov-2019 $5.71M $9.7M Completed Clinical Trials - Phase 2
1. Later Stage VC (Series A) 22-Jun-2018 $4M $4M Completed Clinical Trials - Phase 2
To view Elixirgen Therapeutics’s complete valuation and funding history, request access »

Elixirgen Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-3
Series A-2
Series A-1 609,412 $0.000010 8% $6.56 $6.56 1x $6.56 12.98%
To view Elixirgen Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Elixirgen Therapeutics Patents

  • 67

    Total Documents Applications and Grants

  • Total Patents Families

  • 29

    Granted

  • 27

    Pending

  • Expiring in next 12 mo

Elixirgen Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025226713-A1 Compositions and methods for producing active proteins from inactive proproteins Pending 23-Apr-2024
AU-2025251142-A1 Methods for expression of protein from synthetic mrna delivered by injection Pending 05-Apr-2024
WO-2025212951-A1 Methods for expression of protein from synthetic mrna delivered by injection Pending 05-Apr-2024
AU-2024222304-A1 Synthetic mrna lacking a polya tail or having a short adenine homopolymer and methods of use and production thereof Pending 14-Feb-2023
EP-4665858-A1 Synthetic mrna lacking a polya tail or having a short adenine homopolymer and methods of use and production thereof Pending 14-Feb-2023 C12N15/86
To view Elixirgen Therapeutics’s complete patent history, request access »

Elixirgen Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Elixirgen Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Sunovion Pharmaceuticals Corporation Minority
The University of Tokyo Edge Capital Venture Capital Minority
To view Elixirgen Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

Elixirgen Therapeutics FAQs

  • When was Elixirgen Therapeutics founded?

    Elixirgen Therapeutics was founded in 2012.

  • Where is Elixirgen Therapeutics headquartered?

    Elixirgen Therapeutics is headquartered in Baltimore, MD.

  • What is the size of Elixirgen Therapeutics?

    Elixirgen Therapeutics has 14 total employees.

  • What industry is Elixirgen Therapeutics in?

    Elixirgen Therapeutics’s primary industry is Drug Discovery.

  • Is Elixirgen Therapeutics a private or public company?

    Elixirgen Therapeutics is a Private company.

  • What is Elixirgen Therapeutics’s current revenue?

    The current revenue for Elixirgen Therapeutics is .

  • How much funding has Elixirgen Therapeutics raised over time?

    Elixirgen Therapeutics has raised $29.1M.

  • Who are Elixirgen Therapeutics’s investors?

    Sunovion Pharmaceuticals and The University of Tokyo Edge Capital have invested in Elixirgen Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process